Printer Friendly

A. L. LABORATORIES REPORTS FIRST QUARTER EARNINGS

 A. L. LABORATORIES REPORTS FIRST QUARTER EARNINGS
 FORT LEE, N.J., May 13 /PRNewswire/ -- A. L. Laboratories, Inc.


(NYSE: BMD) today reported that for its first quarter ended March 31, 1992, total revenue for its first quarter ended March 31, 1992, total revenue from continuing operations increased 13 percent to $71,216,000 compared with $63,106,000 in 1991. Net income from continuing operations increased 51 percent to $3,568,000 from $2,356,000 in the first quarter last year. Per share earnings from continuing operations on a fully diluted basis rose 43 percent to $.20 compared with $.14 in the same period of 1991.
 Consistent with the company's stated intention to concentrate on higher margin specialty products, the company expects to divest the remaining portion of its low-margin Human Nutrition business in September 1992. The company had previously sold trademarks related to its European-based Human Nutrition business in the first quarter of 1991. Effective with the first quarter of 1992, as required, the company is reporting the results of its Human Nutrition business as a discontinued operation.
 For the three months ended March 31, 1992, net income from discontinued operations was $388,000 or $.02 per share. Including the income recorded in the first quarter of 1991 related to the sale of tradema a multinational manufacturer and marketer of specialized value-added, branded pharmaceuticals and animal health micronutrients, with plant sites in Chicago Heights, Ill., Niagara Falls and Glendale, N.Y.; Baltimore; Bellevue, Wash.; Copenhagen, Denmark; and Jakarta, Indonesia.
 A. L. LABORATORIES, INC.
 Consolidated Statements of Income
 (In thousands, except per share data)
 (unaudited)
 Three months ended March 31 1992 1991(A)
 Total revenue $71,216 $63,106
 Cost of sales 38,956 33,804
 Gross profit 32,206 29,302
 S,G&A expenses 23,378 21,737
 Operating income 8,882 7,565
 Interest expense (3,071) (3,033)
 Other, net 236 129
 Income from continuing operations
 before provision for income taxes 6,047 4,661
 Provision for income taxes 2,479 2,305
 Income from continuing operations 3,568 2,356
 Income from discontinued
 operations, net of tax 388 1,948
 Net income 3,956 4,304
 Average common shares outstanding:
 Primary 17,086 16,858
 Fully diluted 21,558 21,507
 Earnings per common share:
 Primary
 Income from continuing operations $.21 $.14
 Net income $.23 $.26
 Fully diluted
 Income from continuing operations $.20 $.14
 Net income $.22 $.24
 Dividend per common share $.045 $.04
 (A) Restated to reflect the Human Nutrition business as a discontinued operation.
 A. L. LABORATORIES, INC.
 Financial Position
 (In thousands)
 3/31/92 12/31/91
 (Unaudited) (Audited)
 Current assets $142,096 $159,540
 Non-current assets 194,559 199,290
 Total assets 336,655 358,830
 Current liabilities 84,121 105,720
 Long-term debt:
 Senior 59,193 59,197
 7-3/4 percent subordinated
 convertible debentures 59,511 60,197
 Deferred taxes and
 other liabilities 19,585 19,710
 Stockholders' equity 114,245 114,006
 Total liabilities and
 stockholders equity 336,655 358,830
 -0- 5/13/92
 /CONTACT: Iris D. Daniels of A. L. Laboratories, 201-947-7774, or David Walke of Morgen-Walke, 212-986-5900, for A. L. Laboratories/
 (BMD) CO: A. L. Laboratories, Inc. ST: New Jersey IN: MTC SU: ERN


KD -- NYW009 -- 9461 05/13/92 08:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 13, 1992
Words:548
Previous Article:UNIGENE LABORATORIES EXTENDS CLASS B WARRANT EXPIRATION DATE
Next Article:ARKANSAS BEST COMMENCES INITIAL PUBLIC OFFERING OF 15,700,000 SHARES OF COMMON STOCK; EXTENDS EXPIRATION DATE OF OFFER TO PURCHASE NOTES
Topics:


Related Articles
A. L. LABORATORIES REPORTS 1991 FULL-YEAR AND FOURTH QUARTER EARNINGS
A.L. LABORATORIES REPORTS SECOND QUARTER AND SIX MONTHS RESULTS
PHARMAKINETICS LABORATORIES, INC., RELEASES FIRST QUARTER RESULTS
A. L. LABORATORIES REPORTS THIRD QUARTER AND NINE MONTH RESULTS
A. L. LABORATORIES REPORTS 1992 FULL-YEAR AND FOURTH QUARTER EARNINGS
A. L. LABORATORIES REPORTS FIRST QUARTER EARNINGS
ABBOTT REPORTS INCREASE IN SALES, EARNINGS IN SECOND QUARTER; EARNINGS PER SHARE UP 13.5 PERCENT
A. L. LABORATORIES REPORTS SECOND QUARTER AND SIX MONTH RESULTS
A. L. LABORATORIES REPORTS THIRD QUARTER AND NINE MONTH RESULTS
A. L. LABORATORIES ISSUES CORRECTION TO IBES EARNINGS ESTIMATE FOR THE THIRD QUARTER 1993

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters